SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001479290-23-000030
Filing Date
2023-02-28
Accepted
2023-02-28 17:01:32
Documents
5
Effectiveness Date
2023-02-28

Document Format Files

Seq Description Document Type Size
1 S-8 rvncs-8evergreen2023.htm S-8 92924
2 EX-FILING FEES exhibit107_calculationoffi.htm EX-FILING FEES 21870
3 EX-5.1 exhibit_51opinionofhonigma.htm EX-5.1 8075
4 EX-23.1 exhibit_231xpwcconsentxrvn.htm EX-23.1 2335
5 EX-99.2 exhibit992_rvncs-82023.htm EX-99.2 70032
  Complete submission text file 0001479290-23-000030.txt   196257
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-270130 | Film No.: 23686903
SIC: 2834 Pharmaceutical Preparations